SCHEMBL1480382

SCHEMBL1480382

COc1ccc(C=Cc2nc(-c3ccc(Cl)cc3Cl)cn2CC(=O)N(C(C)C)C(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
CNR1 P21554 2/20 0.39
MAOB P27338 2/20 0.39
EGFR P00533 1/20 0.37
KDR P35968 1/20 0.37
AHR P35869 1/20 0.37
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
SRD5A2 P31213 1/20 0.36
CALCRL Q16602 1/20 0.36
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
PKM P14618 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
THPO P40225 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480379 1.00 MAPT (0.39) MAPTCNR1MAOBEGFRKDR
SCHEMBL1481478 0.87 MAPT (0.43) MAPTCNR1MAOBAHRCXCR2
SCHEMBL1481479 0.87 MAPT (0.43) MAPTCNR1MAOBAHRCXCR2
SCHEMBL1481592 0.85 MARS1 (0.42) MAPTCNR1MAOBGABRA2GABRB2
SCHEMBL1481595 0.85 MARS1 (0.42) MAPTCNR1MAOBGABRA2GABRB2
SCHEMBL1480963 0.84 CNR1 (0.45) MAPTCNR1MAOBCYP3A4PKM
SCHEMBL1480965 0.84 CNR1 (0.45) MAPTCNR1MAOBCYP3A4PKM
SCHEMBL1481462 0.83 RELA (0.40) MAPTCNR1MAOBAHRPKM
SCHEMBL1481457 0.83 RELA (0.40) MAPTCNR1MAOBAHRPKM
SCHEMBL1481375 0.82 MAPT (0.41) MAPTCNR1TP53CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885CNR1 3369/4885MAOB 810/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885CNR1 3369/4885MAOB 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.